Accelerating therapeutic innovation
Dr CLAUDE BERTRAND
Executive Vice President Research & Development
To achieve the objectives the Group has set for 2025, R&D has developed an initial three-year action plan that focuses on three core activities. De novo innovation is about discovering and developing new treatments to address critical needs in oncology, on the one hand, and neurology and immune-inflammation on the other. Life Cycle Management is designed to boost the Group’s existing business, in particular in cardiometabolic diseases. Employeeos working in R&D have demonstrated remarkable agility and commitment since the start of the Covid-19 pandemic, which has enabled us to continue our activities without suffering any delays to our clinical trials. This is very encouraging as the transformation project we are embarking upon relies on the ability of our teams to bounce back.